B-Cell Malignancies—Expert Guidance on BTK Inhibitors for Today’s Clinic

In this clinic-focused program, review the latest data on current and emerging strategies leveraging BTK inhibitors to manage MCL, CLL, and other B-cell malignancies with an on-demand Webcast capturing expert discussion from the 2019 meeting in Chicago. Then download the meeting slidesets to help guide your treatment decisions.
Andrew D. Zelenetz, MD, PhD
Program Director
John C. Byrd, MD
Ian W. Flinn, MD, PhD

On-Demand Webcast

In this on-demand Webcast of a CCO symposium at ASCO 2019, expert faculty review and discuss the latest data on using BTK inhibitors in the treatment of patients with B-cell malignancies.

Andrew D. Zelenetz, MD, PhD
Program Director
John C. Byrd, MD Ian W. Flinn, MD, PhD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: July 11, 2019 Expired: July 10, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?